Multicenter phase II study of brequinar sodium in patients with advanced gastrointestinal cancer
dc.contributor.author | Neidhart, James | en_US |
dc.contributor.author | Dallaire, Brian | en_US |
dc.contributor.author | Sisk, Regina | en_US |
dc.contributor.author | Gyves, John W. | en_US |
dc.contributor.author | Moore, Malcolm | en_US |
dc.contributor.author | Maroun, Jean | en_US |
dc.contributor.author | Robert, Francisco | en_US |
dc.contributor.author | Natale, Ronald B. | en_US |
dc.date.accessioned | 2006-09-11T15:45:00Z | |
dc.date.available | 2006-09-11T15:45:00Z | |
dc.date.issued | 1993-02 | en_US |
dc.identifier.citation | Moore, Malcolm; Maroun, Jean; Robert, Francisco; Natale, Ronald; Neidhart, James; Dallaire, Brian; Sisk, Regina; Gyves, John; (1993). "Multicenter phase II study of brequinar sodium in patients with advanced gastrointestinal cancer." Investigational New Drugs 11(1): 61-65. <http://hdl.handle.net/2027.42/45168> | en_US |
dc.identifier.issn | 0167-6997 | en_US |
dc.identifier.issn | 1573-0646 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/45168 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=8349438&dopt=citation | en_US |
dc.description.abstract | Eighty-six patients with advanced colorectal, gastric or pancreatic carcinoma and no prior exposure to chemotherapy were treated with brequinar sodium. Brequinar was administered at a median weekly dose of 1200 mg/m 2 intravenously. The toxicity was moderate, with thirty patients (35%) experiencing grade 3 or 4 toxicity. Objective responses were observed in 1/32 evaluable colorectal and 2/29 evaluable gastric carcinoma patients. There were no objective responses in 17 evaluable pancreatic cancer patients. We conclude that, at this dose and schedule, brequinar does not have sufficient activity in these gastrointestinal malignancies to warrant further evaluation. | en_US |
dc.format.extent | 312155 bytes | |
dc.format.extent | 3115 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.language.iso | en_US | |
dc.publisher | Kluwer Academic Publishers; Springer Science+Business Media | en_US |
dc.subject.other | Medicine & Public Health | en_US |
dc.subject.other | Pharmacology/Toxicology | en_US |
dc.subject.other | Oncology | en_US |
dc.subject.other | Gastrointestinal Carcinoma | en_US |
dc.subject.other | Brequinar Sodium | en_US |
dc.subject.other | Phase II | en_US |
dc.title | Multicenter phase II study of brequinar sodium in patients with advanced gastrointestinal cancer | en_US |
dc.type | Article | en_US |
dc.subject.hlbsecondlevel | Chemical Engineering | en_US |
dc.subject.hlbsecondlevel | Chemistry | en_US |
dc.subject.hlbsecondlevel | Biological Chemistry | en_US |
dc.subject.hlbsecondlevel | Radiology | en_US |
dc.subject.hlbtoplevel | Engineering | en_US |
dc.subject.hlbtoplevel | Science | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | University of Michigan, Ann Arbor, MI | en_US |
dc.contributor.affiliationother | University of New Mexico Cancer Center, Albuquerque, NM | en_US |
dc.contributor.affiliationother | The DuPont Pharmaceutical Co., Wilmington, DE, USA | en_US |
dc.contributor.affiliationother | The DuPont Pharmaceutical Co., Wilmington, DE, USA | en_US |
dc.contributor.affiliationother | The DuPont Pharmaceutical Co., Wilmington, DE, USA | en_US |
dc.contributor.affiliationother | Princess Margaret Hospital, Toronto, Can | en_US |
dc.contributor.affiliationother | Ottawa Regional Cancer Center, Ottawa, Can | en_US |
dc.contributor.affiliationother | San Juan Veterans' Hospital, San Juan Puerto Rico; University of Alabama at Birmingham, Birmingham, AL, USA | en_US |
dc.contributor.affiliationumcampus | Ann Arbor | en_US |
dc.identifier.pmid | 8349438 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/45168/1/10637_2004_Article_BF00873913.pdf | en_US |
dc.identifier.doi | http://dx.doi.org/10.1007/BF00873913 | en_US |
dc.identifier.source | Investigational New Drugs | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.